Basdai Score Calculator

The BASDAI summarises how active axial spondyloarthritis feels to the patient across five clinical domains, each rated 0 to 10 for the past week: fatigue, spinal pain in the neck, back or hips, peripheral joint pain or swelling, enthesitis measured as discomfort in areas tender to touch or pressure, and morning stiffness. Morning stiffness is asked twice, once for severity and once for duration where 10 corresponds to two hours or more, and the two answers are averaged before the sum is divided by five. That averaging step is the reason the formula is not a simple mean of six items: it keeps morning stiffness from counting twice and gives all five domains equal weight. Enthesitis and morning stiffness are included because they distinguish inflammatory spinal disease from mechanical back pain, which typically improves rather than worsens with rest. A score of 4 or above is the conventional threshold for active disease and appears in ASAS and EULAR treatment pathways as one criterion for escalating to a TNF inhibitor or IL-17 inhibitor after adequate trials of at least two NSAIDs, generally confirmed on two separate occasions rather than a single visit. Response is judged by BASDAI50, meaning a 50 percent relative fall or an absolute drop of 2 units or more. Because every item is self-reported, coexisting fibromyalgia, depression, degenerative disc disease, or obesity can inflate the total without any increase in inflammation, which is why BASDAI scores sometimes diverge sharply from CRP levels and MRI findings.

The index was developed at the Royal National Hospital for Rheumatic Diseases in Bath, England, and published by Sarah Garrett, Andrei Calin, and colleagues in the Journal of Rheumatology in 1994. Their aim was to replace the ad hoc mixture of laboratory values and clinician impressions then used to judge ankylosing spondylitis activity with a short questionnaire that patients could complete themselves in a couple of minutes. It arrived as part of a family of instruments from the same centre, alongside the Bath Ankylosing Spondylitis Functional Index for disability and the Bath Ankylosing Spondylitis Metrology Index for spinal mobility, so that activity, function, and mobility could be tracked as separate axes rather than conflated. BASDAI moved from a research measure to a gatekeeping one when biologic drugs reached the market around 2000 and health systems needed an objective eligibility rule for expensive therapy. Threshold values built into national reimbursement criteria, including those used in the United Kingdom, made the questionnaire part of routine rheumatology practice. Its principal limitation, the absence of any objective inflammatory marker, motivated the development of the Ankylosing Spondylitis Disease Activity Score, which combines patient-reported items with CRP or ESR and was endorsed by ASAS in 2009. ASDAS discriminates better between activity states, and guidelines increasingly prefer it, but BASDAI remains widely used because of its simplicity and the long historical record accumulated with it.